Elsevier Science, Inc.

SHERPA: Unknown

People

  1. Scher
    Scher
  2. Motzer
    Motzer
  3. Bajorin
    Bajorin
  4. Morris
    Morris
  5. Reuter
    Reuter
  6. Rosenberg
    Rosenberg
  7. Sheinfeld
    Sheinfeld
  8. Feldman
    Feldman
  9. Russo
    Russo
  10. Solit
    Solit

Groups

  1. Department of Medicine (389)
  2. Genitourinary Oncology Service (389)
  3. Solid Tumor Oncology Division (389)
  4. Surgery (113)
  5. Urology (109)
  6. Department of Pathology and Laboratory Medicine (65)
  7. Survivorship Research (59)
  8. GSK Faculty (58)
  9. Epidemiology and Biostatistics (51)
  10. Human Oncology and Pathogenesis Program (41)
Search Within
  1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (318)
  2. Meeting Abstract (26)
  3. Review (14)
  4. Correspondence (12)
  5. Editorial (10)
  6. Conference Paper (4)
  7. Research Letter (3)
  8. Guidelines (2)
Groups
  1. Department of Medicine (389)
  2. Genitourinary Oncology Service (389)
  3. Solid Tumor Oncology Division (389)
  4. Surgery (113)
  5. Urology (109)
  6. Department of Pathology and Laboratory Medicine (65)

More Groups

People
  1. Howard Scher (119)
  2. Robert Motzer (111)
  3. Dean Bajorin (58)
  4. Michael Morris (39)
  5. Jonathan Rosenberg (35)
  6. Victor Reuter (35)

More People

Years
  1. 2025 (8)
  2. 2024 (21)
  3. 2023 (28)
  4. 2022 (18)
  5. 2021 (20)
  6. 2020 (23)

More Years

Publications
  1. European Urology (118)
  2. Journal of Urology (101)
  3. Lancet Oncology (52)
  4. Urology (52)
  5. Lancet (14)
  6. Value in Health (12)

More Publications

Results (389)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Reply to Timothée Olivier, Kerrington Powell, Vinay Prasad. Lutetium-177-PSMA-617 in metastatic castration-resistant prostate cancer: Limitations of the VISION trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.022
    Editorial

    Morris, M. J.; Sartor, O.; de Bono, J. S.; Fizazi, K.; Tagawa, S. T.
    European Urology (2023)

    Fulltext@MSK | Save
  • Health-related quality of life and pain outcomes with [(177)Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): A multicentre, open-label, randomised, phase 3 trial
    Journal Article

    Fizazi, K.; Herrmann, K.; Krause, B. J.; Rahbar, K.; Chi, K. N.; Morris, M. J.; Sartor, O.; Tagawa, S. T.; Kendi, A. T.; Vogelzang, N.; more...
    Lancet Oncology (2023)

    Fulltext@MSK | Save
  • Genome-wide association study of bladder cancer reveals new biological and translational insights
    Journal Article

    Koutros, S.; Kiemeney, L. A.; Pal Choudhury, P.; Milne, R. L.; Lopez de Maturana, E.; Ye, Y.; Joseph, V.; Florez-Vargas, O.; Dyrskjøt, L.; Figueroa, J.; more...
    European Urology (2023)

    Fulltext@MSK | Save
  • Disease-free survival analysis for patients with high-risk muscle-invasive urothelial carcinoma from the randomized CheckMate 274 trial by PD-L1 combined positive score and tumor cell score
    Journal Article

    Galsky, M. D.; Bajorin, D. F.; Witjes, J. A.; Gschwend, J. E.; Tomita, Y.; Nasroulah, F.; Li, J.; Collette, S.; Valderrama, B. P.; Grimm, M. O.; more...
    European Urology (2023)

    Fulltext@MSK | Save
  • Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2)
    Review

    Seifert, R.; Emmett, L.; Rowe, S. P.; Herrmann, K.; Hadaschik, B.; Calais, J.; Giesel, F. L.; Reiter, R.; Maurer, T.; Heck, M.; more...
    European Urology (2023)

    Fulltext@MSK | Save
  • Clinical impact of a rapid genetic testing model for advanced prostate cancer patients
    Journal Article

    Breen, K. E.; Symecko, H.; Spielman, K.; Gebert, R.; Shah, I. H.; Pundock, S.; Batson, M.; Narayan, V. K.; Stadler, Z. K.; Autio, K. A.; more...
    Journal of Urology (2023)

    Fulltext@MSK | Save
  • Final results of a phase I trial of WST-11 (TOOKAD Soluble) vascular-targeted photodynamic therapy for upper tract urothelial carcinoma
    Journal Article

    Yip, W.; Sjoberg, D. D.; Nogueira, L. M.; Tracey, A. T.; Alvim, R. G.; Reisz, P. A.; Demac, Q.; Benfante, N. E.; Vanden Berg, R. W.; Kim, K.; more...
    Journal of Urology (2023)

    Fulltext@MSK | Save
  • Evaluation of women with a positive urine cytology and no demonstrable disease in the urinary tract
    Review

    Donat, S. M.; Sonoda, Y.; Al-Ahmadie, H.; Murali, R.; Ng, D. L.; Funt, S. A.; Park, K. J.
    Urology (2023)

    Fulltext@MSK | Save
  • Progression-free survival after second line of therapy for metastatic clear cell renal cell carcinoma in patients treated with first-line immunotherapy combinations
    Research Letter

    Fitzgerald, K. N.; Duzgol, C.; Knezevic, A.; Shapnik, N.; Kotecha, R.; Aggen, D. H.; Carlo, M. I.; Shah, N. J.; Voss, M. H.; Feldman, D. R.; more...
    European Urology (2023)

    Fulltext@MSK | Save
  • Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): A double-blind, randomised, phase 3 trial
    Journal Article

    Motzer, R. J.; Russo, P.; Grünwald, V.; Tomita, Y.; Zurawski, B.; Parikh, O.; Buti, S.; Barthélémy, P.; Goh, J. C.; Ye, D.; more...
    Lancet (2023)

    Fulltext@MSK | Save